Top 5 AJMC® Articles of October 2019

Hi, this is Laura Joszt for The American Journal of Managed Care®. Here are the top 5 articles for the month of October.

Number 5: New research has found that patients with relapsed or refractory multiple myeloma experience declines in health status and quality of life 2 to 3 months before progression of the underlying malignant disease.

Number 4: Patients 12 years and older with cystic fibrosis with the most common genetic mutation will have a new treatment available. FDA Commissioner Dr Ned Sharpless called the approval of Trikafta “landmark” because it will provide treatment to most patients with cystic fibrosis who previously had no options.

Number 3: More than 2 years after the FDA derailed the trajectory of its novel treatment system for type 2 diabetes, Intarcia Therapeutics announced that regulators have accepted a resubmitted new drug application for the mini pump that delivers a continuous dose of exenatide.

Number 2: Researchers at Yale School of Medicine announced that an experimental drug tested in nonhuman primates was able to reverse nonalcoholic fatty liver disease, which is a precursor to heart disease and type 2 diabetes, while also driving down levels of low-density lipoprotein cholesterol. NAFLD is a condition that has been on the rise among Americans as obesity rates have increased.

Number 1: In an effort to educate clinicians about the issue of forcing patients in pain to suddenly halt opioid use, HHS released a guide that emphasizes patient-centered care and recommends against a rapid taper or stopping opioids all at once.

To read all of these articles and more, visit ajmc.com.